Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant with or without LY2835219 (abemaciclib) in HR+, HER2- advanced breast cancer
2013-004728-13Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Abemaciclib + fulvestrant with Placebo + fulvestrant (2 arms). Primary endpoint: Progression-free survival. Started May 2014; status: active.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004728-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004728-13.